Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 3
2004 3
2005 3
2006 3
2007 1
2008 4
2009 4
2010 5
2011 8
2012 7
2013 11
2014 6
2015 8
2016 6
2017 3
2018 12
2019 6
2020 12
2021 12
2022 7
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma.
Giralt S, Jolles S, Kerre T, Lazarus HM, Mustafa SS, Papanicolaou GA, Ria R, Vinh DC, Wingard JR. Giralt S, et al. Among authors: ria r. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):719-732. doi: 10.1016/j.clml.2023.05.008. Epub 2023 May 23. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37353432 Free article. Review.
Angiogenesis in multiple myeloma.
Vacca A, Ria R, Reale A, Ribatti D. Vacca A, et al. Among authors: ria r. Chem Immunol Allergy. 2014;99:180-96. doi: 10.1159/000353312. Epub 2013 Oct 17. Chem Immunol Allergy. 2014. PMID: 24217610 Review.
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma.
Saltarella I, Desantis V, Melaccio A, Solimando AG, Lamanuzzi A, Ria R, Storlazzi CT, Mariggiò MA, Vacca A, Frassanito MA. Saltarella I, et al. Among authors: ria r. Cells. 2020 Jan 9;9(1):167. doi: 10.3390/cells9010167. Cells. 2020. PMID: 31936617 Free PMC article. Review.
Identify multiple myeloma stem cells: Utopia?
Saltarella I, Lamanuzzi A, Reale A, Vacca A, Ria R. Saltarella I, et al. Among authors: ria r. World J Stem Cells. 2015 Jan 26;7(1):84-95. doi: 10.4252/wjsc.v7.i1.84. World J Stem Cells. 2015. PMID: 25621108 Free PMC article. Review.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Gentile M, Vigna E, Palmieri S, Galli M, Derudas D, Mina R, Della Pepa R, Zambello R, Martino EA, Bruzzese A, Mangiacavalli S, Zamagni E, Califano C, Musso M, Conticello C, Cerchione C, Mele G, Di Renzo N, Offidani M, Tarantini G, Casaluci GM, Rago A, Ria R, Uccello G, Barilà G, Palumbo G, Pompa A, Vincelli D, Brunori M, Accardi F, Amico V, Amendola A, Fontana R, Bongarzoni V, Rossini B, Cotzia E, Gozzetti A, Rizzi R, Sgherza N, Ferretti E, Bertuglia G, Nappi D, Petrucci MT, Di Raimondo F, Neri A, Morabito F, Musto P. Gentile M, et al. Among authors: ria r. Haematologica. 2024 Jan 1;109(1):245-255. doi: 10.3324/haematol.2023.283251. Haematologica. 2024. PMID: 37439329 Free PMC article.
115 results